- Memic's Hominis® platform is the first and only FDA-authorized surgical robot that features miniature humanoid-shaped arms, with shoulder, elbow, and wrist joints, providing human level dexterity and 360-degree articulation
- Hominis' small, compact, and mobile design occupies a minimal footprint at a significant cost advantage compared to available robotic technology
- The first FDA-authorized indication of Hominis is in women's health, including benign hysterectomy via the transvaginal approach, which is known to offer less pain, lower infection rates, faster recovery, and no visible scarring
- The MedTech Acquisition Corporation management team and board of directors bring decades of medical device and surgical robotics commercialization experience
- The combined companies are valued at an estimated pro-forma equity value of more than $1 billion, assuming no redemptions by MedTech's public stockholders
- The Company will have approximately $360 million in pro forma cash on the balance sheet, assuming no redemptions by public stockholders of MedTech, less transactional expenses and operational expenses through closing, to support ongoing commercialization in women's healthcare and development of additional Hominis robot-assisted surgical applications
- The business combination is supported by a $76 million PIPE with participation from leading investors, including Bridger Healthcare, Ltd., The Kraft Group, Monashee Investment Management LLC, Pura Vida Investments, Wellington Management, Ken Langone, Peregrine Ventures, HighSage Ventures, and management and board members of MedTech
PR Newswire
TEL AVIV, Israel and FORT LAUDERDALE, Fla., Aug. 13, 2021
